Channel Therapeutics Corporation (CHRO)
NYSEAMERICAN: CHRO · Real-Time Price · USD
0.631
-0.009 (-1.37%)
Dec 24, 2024, 12:59 PM EST - Market closed
Channel Therapeutics Statistics
Total Valuation
CHRO has a market cap or net worth of $3.80 million. The enterprise value is $4.84 million.
| Market Cap | 3.80M |
| Enterprise Value | 4.84M |
Important Dates
The last earnings date was Wednesday, November 13, 2024, after market close.
| Earnings Date | Nov 13, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
CHRO has 6.03 million shares outstanding. The number of shares has increased by 333.40% in one year.
| Current Share Class | 6.03M |
| Shares Outstanding | 6.03M |
| Shares Change (YoY) | +333.40% |
| Shares Change (QoQ) | +0.32% |
| Owned by Insiders (%) | 20.34% |
| Owned by Institutions (%) | 2.14% |
| Float | 1.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.60
| Current Ratio | 0.60 |
| Quick Ratio | 0.35 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.48 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -556.33% |
| Return on Capital (ROIC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.26M |
| Employee Count | 8 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 0.66 |
| 200-Day Moving Average | 1.23 |
| Relative Strength Index (RSI) | 47.81 |
| Average Volume (20 Days) | 162,216 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
| Revenue | n/a |
| Gross Profit | -3.19M |
| Operating Income | -9.63M |
| Pretax Income | -8.98M |
| Net Income | -10.07M |
| EBITDA | n/a |
| EBIT | -9.63M |
| Earnings Per Share (EPS) | -$2.20 |
Balance Sheet
The company has $1.25 million in cash and $2.29 million in debt, giving a net cash position of -$1.03 million or -$0.17 per share.
| Cash & Cash Equivalents | 1.25M |
| Total Debt | 2.29M |
| Net Cash | -1.03M |
| Net Cash Per Share | -$0.17 |
| Equity (Book Value) | -1.43M |
| Book Value Per Share | -0.25 |
| Working Capital | -1.43M |
Cash Flow
| Operating Cash Flow | -5.48M |
| Capital Expenditures | n/a |
| Free Cash Flow | -5.48M |
| FCF Per Share | -$0.91 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CHRO does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -333.40% |
| Shareholder Yield | -333.40% |
| Earnings Yield | -264.60% |
| FCF Yield | -144.00% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | Strong Buy |
| Analyst Count | 1 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |